Segall Bryant & Hamill LLC Has $6.40 Million Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Segall Bryant & Hamill LLC raised its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 28.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 46,870 shares of the company's stock after acquiring an additional 10,398 shares during the quarter. Segall Bryant & Hamill LLC's holdings in Neurocrine Biosciences were worth $6,398,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Caprock Group LLC acquired a new stake in shares of Neurocrine Biosciences during the fourth quarter worth $236,000. Charles Schwab Investment Management Inc. grew its position in shares of Neurocrine Biosciences by 2.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 762,557 shares of the company's stock worth $104,089,000 after buying an additional 15,266 shares during the period. Tri Ri Asset Management Corp bought a new stake in shares of Neurocrine Biosciences in the 3rd quarter valued at about $3,236,000. Oakworth Capital Inc. acquired a new stake in shares of Neurocrine Biosciences in the 4th quarter valued at approximately $379,000. Finally, Synergy Asset Management LLC bought a new position in Neurocrine Biosciences during the 4th quarter worth approximately $996,000. Institutional investors and hedge funds own 92.59% of the company's stock.

Insider Activity

In other news, insider Ingrid Delaet sold 272 shares of the company's stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $138.10, for a total transaction of $37,563.20. Following the completion of the sale, the insider now owns 2,507 shares of the company's stock, valued at approximately $346,216.70. This represents a 9.79 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Kyle Gano sold 65,000 shares of the business's stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $141.50, for a total value of $9,197,500.00. Following the transaction, the chief executive officer now directly owns 135,392 shares of the company's stock, valued at $19,157,968. This trade represents a 32.44 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 233,178 shares of company stock valued at $33,906,594 over the last ninety days. 4.30% of the stock is currently owned by company insiders.

Remove Ads

Neurocrine Biosciences Price Performance

NBIX stock traded down $0.84 during trading hours on Friday, reaching $113.16. The stock had a trading volume of 800,768 shares, compared to its average volume of 981,987. The stock has a market capitalization of $11.28 billion, a PE ratio of 34.40, a price-to-earnings-growth ratio of 0.77 and a beta of 0.35. The stock has a 50-day simple moving average of $124.17 and a 200 day simple moving average of $124.94. Neurocrine Biosciences, Inc. has a fifty-two week low of $105.18 and a fifty-two week high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The company reported $1.00 EPS for the quarter, missing analysts' consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 13.38% and a net margin of 14.49%. On average, sell-side analysts forecast that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current fiscal year.

Neurocrine Biosciences declared that its Board of Directors has approved a stock buyback program on Friday, February 21st that authorizes the company to buyback $500.00 million in outstanding shares. This buyback authorization authorizes the company to repurchase up to 4.2% of its shares through open market purchases. Shares buyback programs are generally a sign that the company's management believes its shares are undervalued.

Analysts Set New Price Targets

Several equities research analysts have weighed in on NBIX shares. HC Wainwright reiterated a "buy" rating and issued a $185.00 target price on shares of Neurocrine Biosciences in a report on Friday, February 21st. Wedbush reduced their target price on Neurocrine Biosciences from $157.00 to $147.00 and set an "outperform" rating on the stock in a report on Friday, February 7th. Barclays increased their price target on Neurocrine Biosciences from $160.00 to $165.00 and gave the stock an "overweight" rating in a report on Monday, December 23rd. Canaccord Genuity Group cut their price objective on Neurocrine Biosciences from $172.00 to $163.00 and set a "buy" rating on the stock in a report on Friday, February 7th. Finally, StockNews.com cut Neurocrine Biosciences from a "strong-buy" rating to a "buy" rating in a research note on Thursday, March 20th. Five research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $165.38.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.